Company intelligence / Profile preview
ISAR Bioscience
Planegg, Bavaria, Germanyisarbioscience.de ↗
- Ownership
- Private
- Employees
- ~27
- Development stage
- Other
01
Overview
ISAR Bioscience develops regenerative therapies using iPS cells and differentiated human cells to address dementia, heart failure, immune diseases, and infectious diseases. Their pipeline includes early-stage programs targeting TREM2 for cognition disorders and nanobody-based approaches against viral proteins. No clinical results or advanced-stage assets are reported as of mid–2025.
- Therapeutic areas
- Infectious DiseasesImmunologyNeurologyCardiovascular
- Modalities
- Induced pluripotent stem cell derived therapy (iPSC-derived therapy)Monoclonal antibodyNanobody therapyCell therapyGenome engineering-based therapies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on ISAR Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISAR Bioscience.